Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07291232
PHASE1

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

Sponsor: AbbVie

View on ClinicalTrials.gov

Summary

This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.

Official title: A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Multiple Subcutaneous Doses of ABBV-295 in Adult Subjects With Obesity

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

96

Start Date

2025-11-19

Completion Date

2026-10

Last Updated

2025-12-18

Healthy Volunteers

No

Conditions

Interventions

DRUG

ABBV-295

Subcutaneous Injections

DRUG

Placebo

Subcutaneous Injections

Locations (1)

Acpru /Id# 278624

Grayslake, Illinois, United States